ShanXi C&Y Pharmaceutical Group Co., Ltd. (300254.SZ)
CNY 8.56
(2.27%)
CNY 8.56
(2.27%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 261.8 Million CNY | -22.88% |
| 2022 | 339.49 Million CNY | 177.52% |
| 2021 | 122.33 Million CNY | -16.59% |
| 2020 | 146.65 Million CNY | -30.12% |
| 2019 | 209.85 Million CNY | 49.78% |
| 2018 | 140.11 Million CNY | 57.96% |
| 2017 | 88.7 Million CNY | -1.16% |
| 2016 | 89.74 Million CNY | 349.61% |
| 2015 | -35.95 Million CNY | -733.86% |
| 2014 | -4.31 Million CNY | -112.49% |
| 2013 | 34.53 Million CNY | 115.52% |
| 2012 | -222.56 Million CNY | 37.32% |
| 2011 | -355.1 Million CNY | -1631.45% |
| 2010 | -20.5 Million CNY | 42.58% |
| 2009 | -35.71 Million CNY | -205.83% |
| 2008 | 33.75 Million CNY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q3 | -49.97 Million CNY | -118.0% |
| 2024 Q1 | 285.72 Million CNY | 9.13% |
| 2024 Q2 | 277.63 Million CNY | -2.83% |
| 2023 Q2 | -63.03 Million CNY | -124.01% |
| 2023 Q1 | 262.55 Million CNY | -22.66% |
| 2023 Q4 | 261.8 Million CNY | -1.41% |
| 2023 FY | 261.8 Million CNY | -22.88% |
| 2023 Q3 | 265.55 Million CNY | 521.3% |
| 2022 Q4 | 339.49 Million CNY | 7014.44% |
| 2022 FY | 339.49 Million CNY | 177.52% |
| 2022 Q2 | 21.03 Million CNY | -80.81% |
| 2022 Q3 | 4.77 Million CNY | -77.32% |
| 2022 Q1 | 109.65 Million CNY | -10.36% |
| 2021 Q3 | 116.77 Million CNY | -12.9% |
| 2021 Q4 | 122.33 Million CNY | 4.75% |
| 2021 Q2 | 134.07 Million CNY | -12.78% |
| 2021 FY | 122.33 Million CNY | -16.59% |
| 2021 Q1 | 153.71 Million CNY | 4.81% |
| 2020 Q3 | 127.56 Million CNY | -50.72% |
| 2020 Q1 | 235.03 Million CNY | 12.0% |
| 2020 Q2 | 258.88 Million CNY | 10.15% |
| 2020 Q4 | 146.65 Million CNY | 14.96% |
| 2020 FY | 146.65 Million CNY | -30.12% |
| 2019 Q1 | 171.38 Million CNY | 22.32% |
| 2019 FY | 209.85 Million CNY | 49.78% |
| 2019 Q2 | 114.35 Million CNY | -33.27% |
| 2019 Q4 | 209.85 Million CNY | 83.4% |
| 2019 Q3 | 114.42 Million CNY | 0.06% |
| 2018 Q3 | 159.23 Million CNY | 24.71% |
| 2018 FY | 140.11 Million CNY | 57.96% |
| 2018 Q2 | 127.68 Million CNY | 21.04% |
| 2018 Q4 | 140.11 Million CNY | -12.01% |
| 2018 Q1 | 105.48 Million CNY | 18.92% |
| 2017 Q4 | 88.7 Million CNY | -19.17% |
| 2017 FY | 88.7 Million CNY | -1.16% |
| 2017 Q1 | 181.82 Million CNY | 102.59% |
| 2017 Q2 | 176.52 Million CNY | -2.91% |
| 2017 Q3 | 109.74 Million CNY | -37.83% |
| 2016 Q1 | 41.65 Million CNY | 215.84% |
| 2016 FY | 89.74 Million CNY | 349.61% |
| 2016 Q4 | 89.74 Million CNY | 3.36% |
| 2016 Q3 | 86.82 Million CNY | 27.09% |
| 2016 Q2 | 68.32 Million CNY | 64.03% |
| 2015 Q2 | 112.99 Million CNY | 179.99% |
| 2015 Q3 | -62.68 Million CNY | -155.48% |
| 2015 Q4 | -35.95 Million CNY | 42.64% |
| 2015 FY | -35.95 Million CNY | -733.86% |
| 2015 Q1 | 40.35 Million CNY | 1035.92% |
| 2014 Q3 | -42.99 Million CNY | -1151.15% |
| 2014 Q2 | -3.43 Million CNY | -121.99% |
| 2014 Q1 | 15.62 Million CNY | -54.74% |
| 2014 FY | -4.31 Million CNY | -112.49% |
| 2014 Q4 | -4.31 Million CNY | 89.97% |
| 2013 Q1 | -243.77 Million CNY | -9.53% |
| 2013 Q3 | -57.41 Million CNY | 77.98% |
| 2013 Q4 | 34.53 Million CNY | 160.15% |
| 2013 FY | 34.53 Million CNY | 115.52% |
| 2013 Q2 | -260.72 Million CNY | -6.95% |
| 2012 Q3 | -184.51 Million CNY | 3.77% |
| 2012 FY | -222.56 Million CNY | 37.32% |
| 2012 Q2 | -191.73 Million CNY | -0.43% |
| 2012 Q1 | -190.91 Million CNY | 46.24% |
| 2012 Q4 | -222.56 Million CNY | -20.62% |
| 2011 Q4 | -355.1 Million CNY | 9.12% |
| 2011 Q2 | -3.47 Million CNY | 0.0% |
| 2011 Q3 | -390.73 Million CNY | -11153.7% |
| 2011 FY | -355.1 Million CNY | -1631.45% |
| 2010 FY | -20.5 Million CNY | 42.58% |
| 2010 Q4 | -20.5 Million CNY | 0.0% |
| 2009 FY | -35.71 Million CNY | -205.83% |
| 2008 FY | 33.75 Million CNY | 0.0% |